Form 4: Erasca Director Opts for Stock Options Over Cash Compensation

Erasca, Inc. Director James Arthur Bristol received 37,762 stock options with a $3.72 exercise price in lieu of 2026 cash compensation.

Summary

• James Arthur Bristol, a Director of Erasca, Inc. (ERAS), acquired 37,762 stock options on January 1, 2026.
• These options were granted with an exercise price of $3.72 per share.
• The option grant was issued in lieu of the cash compensation payable to Mr. Bristol for his board and committee positions in 2026.
• The options will vest and become exercisable in monthly, cumulative 1/12 increments beginning one month from the grant date.
• Vesting is contingent upon Mr. Bristol's continued service on Erasca's board of directors through the applicable vesting date.
• The options have an expiration date of January 1, 2036.

Sentiment

Score: 7

Explanation: The filing indicates a positive alignment of director and shareholder interests through equity compensation, reflecting confidence in the company's future. It is a routine transaction, not a major operational announcement.

Positives

• The director's election to receive equity compensation instead of cash demonstrates strong alignment with shareholder interests and confidence in the company's long-term growth prospects.
• Equity compensation helps conserve cash for the company, which can be beneficial for operational funding or strategic investments.

Risks

• The vesting of the stock options is subject to the director's continued service on the issuer's board of directors, meaning the options could be forfeited if service ceases prematurely.

Future Outlook

The director's decision to accept stock options in lieu of cash compensation suggests a positive long-term outlook for Erasca, Inc. and an expectation of future stock appreciation.

Management Comments

• The option grant was issued at the election of the filing person in lieu of the cash compensation payable for 2026 board and committee service.
• The options will vest in monthly 1/12 increments, contingent on continued board service.

Industry Context

Equity compensation for directors is a common practice, particularly in the biotechnology and pharmaceutical sectors, as it aligns the interests of board members with those of shareholders and can help conserve cash for R&D or clinical development.

Comparison to Industry Standards

• The practice of granting stock options as compensation to directors is a standard corporate governance mechanism across various industries, especially in growth-oriented companies.
• This aligns director incentives with long-term shareholder value creation, a common benchmark for effective governance.

Corporate Governance

Related Party Transactions

• The grant of stock options to James Arthur Bristol, a director, constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Benefit from increased alignment of director interests with long-term company performance and potential cash conservation.
• Employees: No direct impact mentioned in this filing.

Next Steps

• The director must continue to serve on the board of directors for the options to vest according to the monthly schedule.

Key Dates

Recommendation

The filing reports a routine equity compensation grant to an existing director, which is a positive signal for alignment of interests but does not provide new fundamental information that would significantly alter an investment thesis or warrant a strong buy/sell recommendation.

Keywords

Erasca, ERAS, Form 4, stock option, director compensation, equity compensation, insider transaction, beneficial ownership, corporate governance